RT Journal Article
SR Electronic
T1 A Predictive Autoantibody Signature in Multiple Sclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.01.23288943
DO 10.1101/2023.05.01.23288943
A1 Zamecnik, Colin R.
A1 Sowa, Gavin M.
A1 Abdelhak, Ahmed
A1 Dandekar, Ravi
A1 Bair, Rebecca D.
A1 Wade, Kristen J.
A1 Bartley, Christopher M.
A1 Tubati, Asritha
A1 Gomez, Refujia
A1 Fouassier, Camille
A1 Gerungan, Chloe
A1 Alexander, Jessica
A1 Wapniarski, Anne E.
A1 Loudermilk, Rita P.
A1 Eggers, Erica L.
A1 Zorn, Kelsey C.
A1 Ananth, Kirtana
A1 Jabassini, Nora
A1 Mann, Sabrina A.
A1 Ragan, Nicholas R.
A1 Santaniello, Adam
A1 Henry, Roland G.
A1 Baranzini, Sergio E.
A1 Zamvil, Scott S.
A1 Bove, Riley M.
A1 Guo, Chu-Yueh
A1 Gelfand, Jeffrey M.
A1 Cuneo, Richard
A1 von Büdingen, H.-Christian
A1 Oksenberg, Jorge R.
A1 Cree, Bruce AC
A1 Hollenbach, Jill A.
A1 Green, Ari J.
A1 Hauser, Stephen L.
A1 Wallin, Mitchell T.
A1 DeRisi, Joseph L.
A1 Wilson, Michael R.
YR 2023
UL http://medrxiv.org/content/early/2023/05/15/2023.05.01.23288943.abstract
AB Although B cells are implicated in multiple sclerosis (MS) pathophysiology, a predictive or diagnostic autoantibody remains elusive. Here, the Department of Defense Serum Repository (DoDSR), a cohort of over 10 million individuals, was used to generate whole-proteome autoantibody profiles of hundreds of patients with MS (PwMS) years before and subsequently after MS onset. This analysis defines a unique cluster of PwMS that share an autoantibody signature against a common motif that has similarity with many human pathogens. These patients exhibit antibody reactivity years before developing MS symptoms and have higher levels of serum neurofilament light (sNfL) compared to other PwMS. Furthermore, this profile is preserved over time, providing molecular evidence for an immunologically active prodromal period years before clinical onset. This autoantibody reactivity was validated in samples from a separate incident MS cohort in both cerebrospinal fluid (CSF) and serum, where it is highly specific for patients eventually diagnosed with MS. This signature is a starting point for further immunological characterization of this MS patient subset and may be clinically useful as an antigen-specific biomarker for high-risk patients with clinically- or radiologically-isolated neuroinflammatory syndromes.Competing Interest StatementMRW receives unrelated research grant funding from Roche/Genentech and Novartis, and has received speaking honoraria from Genentech, Takeda, WebMD and Novartis.Funding StatementThis work was supported by the Valhalla Foundation (SLH, MRW, JRO, BAC), the Westridge Foundation (MRW, HCvB, AJG), NINDS R35NS122073 (SLH, MRW and RD), National Multiple Sclerosis Society RFA-2104-37504 (MRW, MTW, JH, BAC, CRZ), NMSS RFA-2104-3747 (JRO), Bruce Sachs, the UCSF Dean's Office Medical Student Research Program (GMS), Chan Zuckerberg Biohub (JLD, SAM), John A. Watson Scholar Program, UCSF (CMB), Hanna H. Gray Fellowship, Howard Hughes Medical Institute (CMB), NIH NIH R01AI158861 (JAH and KJW) and the University of California President's Postdoctoral Fellowship Program (CMB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University of California, San Francisco gave ethical approval for this work (14-15278) IRB of Veterans Affairs Medical Center gave ethical approval for this work (IRB-1624644-4)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available online at https://github.com/UCSF-Wilson-Lab/MS_DoD_and_ORIGINS_study_data